US$ 21.64
pharma news today glp-1 obesity drugs drug supply Giants Bet on Next-Generation GLP-1 Treatments A $60 billion industry just
Description
There are a lot of food and beverage manufacturers, and there are not that many products on the market, said Choi
A.HammoudR.RittigN.et al (2024)

Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump trial-a randomized, double-blinded, placebo-controlled trial

July 7, 2025
Although the current data is insufficient to strongly advocate for the cardiovascular benefits of dual and triple agonists, ongoing trials suggest potential improvements in cardiometabolic risk factors, such as reduced blood pressure, triglycerides, and LDL-C levels
Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, et al